An ongoing randomised phase II study (NCT03727880) is looking into the effectiveness and safety of combining standard pancreatic cancer chemotherapy, prior and post-surgery, and pembrolizumab with or without the FAK inhibitor defactinib, in patients with high-risk resectable pancreatic cancer. This evidence concerns the gene PTK2 and familial pancreatic carcinoma.